15
May

06:00 PM CEST

Medicinal Chemistry Strategy Dinner

Season 52, 3535 US-1 Suite 100B Princeton, NJ 08540

FULLY BOOKED

What to expect

Timely information, interactive format

Join us for dinner, drinks and discussions on how technology and geopolitics is shaping the future of drug discovery.

Curia was the first discovery CRO and has grown to provide a breadth of services to support clients research and development needs.

Engage in conversation with peers and Curia’s expert medicinal chemists in understanding how technology and geopolitics is shaping the way discovery outsourcing is done.

Curia, from Curiosity to Cure.

Our Agenda

Why you should attend

At Curia the journey to medical breakthrough may be linear, but it’s never simple. From discovery through manufacturing, launch through commercialization, we leverage deep scientific expertise and state-of-the-art technology to ensure every stage of this intricate process advances as quickly and accurately as possible.

Meet Our Facilitator

Christopher Conway

President, Research and Development Curia

Chris is a seasoned business executive with a 25 year strong track record across a variety of industry verticals including aerospace, pharmaceutical/biotech and contract research, development, and manufacturing. Chris is highly experienced in P&L leadership, sales, and marketing having worked in large and small, public and private equity backed companies. Currently, Chris serves as President and R&D Business Unit Head at Curia, a global top ten organization in contract research, development and manufacturing services, serving the pharmaceutical/biotech industry. Chris also currently serves as a Director on the board of two Life Sciences organizations including Viyash Life Sciences Private Limited, a Carlyle owned company, as well as the Drug, Chemical & Associated Technologies Association, Inc. (DCAT). Chris received his B.S. in Marketing & Management from Siena College and his Doctorate of Humane Letters from the Albany College of Pharmacy and Health Sciences

Dr. Grant Carr

Vice President, Head of Global R&D Drug Discovery Curia

Douglas Kitchen

Research Fellow, Medicinal Chemistry Curia

Mark Wolf

Director, Medicinal Chemistry Curia

Mark Wolf, Ph.D. is Director of Medicinal Chemistry at Curia and has over 27 years of drug discovery and development experience. He has led interdisciplinary scientific teams to support large pharma, biotech collaborations and Curia R&D programs. His research has spanned several therapeutic areas including oncology, CNS, pain/inflammation, and respiratory. Mark has experience establishing practical screening strategies to identify drug candidate compounds with a first-in-class or best-in-class product profile. He led Curia’s Tubulin Inhibitor Program which discovered and advancedALB-109564 into a Phase 1 clinical trial for the treatment of solid tumors. His CNS experience includes targets in the areas of pain management (GPCR targets) and antipsychotics based on the hypoglutamate hypothesis (GlyT1 inhibitors). Mark has extensive experience managing multiple external providers and Curia assets in support of discovery and pre clinical development programs. He is named as an inventor/co-inventor on five patents and co-author on 25 peer reviewed publications.

Matthew Surman

Associate Director, Medicinal Chemistry Curia

Matt Surman, Ph.D. is Associate Director of Medicinal Chemistry at Curia Global and has over 20 years of industry experience. He joined the Curia Medicinal Chemistry department in 2002 and worked on contract research projects spanning a variety of therapeutic areas including oncology, anti-infectives and CNS disorders. From 2005 to 2011, he was part of the Curia internal Discovery Research and Development department. His efforts were focused in the area of metabolic disorders, particularly in obesity. He served as the project leader for the Curia MCH-1 antagonist program from 2008 until returning to the Medicinal Chemistry department in late 2011. During that time, the project culminated in the discovery and development of a successful Phase I clinical candidate. Since returning to the Medicinal Chemistry department, Dr. Surman has led the discovery efforts on a number of programs including projects involved in oncology, neurological disease, and pain. Multiple pre-clinical and clinical candidates have arisen from these efforts. Dr. Surman has over 40 peer reviewed publications and patent applications

More about Curia

More information

Curia is a Contract Research, Development and Manufacturing Organization with over 30 years of experience, an integrated network of 27 global sites and over 3,500 employees partnering with customers to make treatments broadly accessible to patients. Our biologics and small molecules offering spans discovery through commercialization, with integrated regulatory and analytical capabilities. Our scientific and process experts and state of the art facilities deliver best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to accelerate and sustain life-changing therapeutics. To learn more visit us at curiaglobal.com

Further Information

Interested in attending this virtual roundtable or running your own? Drop us a message today and we will get in touch

Here To Help

Need help registering your team? Just get in touch and a member of the team will be happy to help.

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

R&D Curia

Curia – Drug Discovery Biology & Bioinformatics Strategy Dinner

Medicinal Chemistry Strategy Dinner

<img class="lazy" decoding="async" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%2012%2016'%3E%3C/svg%3E" data-src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >Season 52, 3535 US-1 Suite 100B Princeton, NJ 08540

Timely information, interactive format

Our Agenda

Registration & Networking With a Signature Cocktail on Arrival

Roundtable Discussion Navigating the impact of geopolitics and ongoing legislation on discovery outsourcing

Roundtable Discussion Finding the right CRO medicinal chemistry partner to improve efficiency and short discovery timelines

Dinner

Closing Remarks and Coffee Dessert Cognac Closing

Why you should attend

Meet Our Facilitator

Christopher Conway

Dr. Grant Carr

Douglas Kitchen

Mark Wolf

Matthew Surman

More about Curia

Further Information

Here To Help

Select days you wish to attend You can add multiple days

VAT Excluded

Select days you wish to attend You can add multiple days

Pass includes:

VAT Excluded

About You

Your Address

About Your Company

This is required field*

Bone/Osteoporosis

Immunology

Orthopaedics

Cardiovascular

Infectious diseases

Pulmonology

CNS

Inflammation

Psychiatry

Dermatology

Internal diseases

Respiratory

Diabetes

Metabolic diseases

Rheumatology

Endocrinology

Nephrology

Surgery

ENT

Neurology

Urology

Gastroenterology

Oncology

Vaccines

Haematology

Ophthalmology

Thrombosis

Rare Diseases

This is required field*

0-10

10-50

50-100

100-500

500+

This is required field*

This is required field*

Under £100,000

£100,000 - £500,000

£500,000 - £1,000,000

£1,000,000 - £5,000,000

£5,000,000 - £10,000,000

£10,000,000 +

This is required field*

This is required field*

Season 52, 3535 US-1 Suite 100B Princeton, NJ 08540